Artiva prices financing after positive AlloNK autoimmune data and FDA alignment on single Phase 3

 

Artiva prices $300M underwritten common stock and pre-funded warrant offering at $11.52 after positive AlloNK autoimmune data and FDA alignment on single Phase 3 trial

• Initial AlloNK data showed 71% ACR50 response in refractory rheumatoid arthritis patients, indicating substantial clinical activity.
• AlloNK clinical results were positive across multiple autoimmune diseases beyond rheumatoid arthritis in early evaluations.
• FDA alignment achieved on a single Phase 3 registrational trial design for AlloNK in autoimmune diseases.
• Reported fiscal Q1 2026 non-GAAP EPS $-0.95 (-14% YoY) on revenue $0, missing EPS but beating revenue estimates.

https://finviz.com/quote?t=ARTV&p=d